Advertisement

Topics

Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

11:49 EDT 31 Aug 2017 | BioPharma-Reporter

Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.

Original Article: Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

NEXT ARTICLE

More From BioPortfolio on "Oxford BioMedica could pocket $100m on Novartis CAR-T cell success"

Quick Search
Advertisement
 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...